Today, current guidelines concerning diabetes management of AHF patients [22] propose that insulin-based glycaemic control should be considered in cases of hyperglycaemia (>10 mmol/L or >180 mg/dL) with the target adapted to possible comorbidities. The gene discussed is INS; the disease is Hyperglycemia.